8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety
and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.